King Faisal Specialist Hospital, Riyadh – United Arab Emirates
About Dr. Ali D. Alahmari
Dr. Ali D. Alahmari is a Consultant in Adult Haematology with focused expertise in acute leukaemia, haematopoietic stem cell transplantation, and sickle cell disease management — a dedicated acute leukaemia specialist in Riyadh, Saudi Arabia providing advanced transplant care to international patients. He is lead author of the first published haploidentical stem cell transplant for sickle cell disease following prior liver transplantation.
- Consultant in Adult Haematology and Stem Cell Therapy specialising in Acute Leukaemia
- Lead author on the first published haplo-SCT after liver transplant for sickle cell disease
- Co-investigator in an international learning collaborative on Haploidentical BMT for Sickle Cell Disease
- Expertise in post-transplant cyclophosphamide protocols and reduced-intensity conditioning
- Experienced in managing adult haematological transplant complications and GvHD
Qualifications & Credentials
Medical Degrees
- MBBS — Bachelor of Medicine and Bachelor of Surgery
- Internal Medicine Residency
Fellowships & Special Training
- Fellowship in Adult Haematology
- Fellowship in Adult Stem Cell Transplantation and Cellular Therapy
- Advanced Training in Haploidentical Bone Marrow Transplantation
Certifications & Accreditations
- Saudi Commission for Health Specialties (SCFHS) — Registered Consultant
- American Society of Hematology (ASH) — Member
- European Society for Blood and Marrow Transplantation (EBMT) — Member
Areas of Expertise
Major Conditions Treated
- Acute Lymphoblastic Leukaemia (ALL)
- Acute Myeloid Leukaemia (AML)
- Chronic Myeloid Leukaemia (CML)
- Myelodysplastic Syndrome (MDS)
- Sickle Cell Disease (Adult)
- Beta-Thalassaemia (Adult)
- Aplastic Anaemia
- Graft-versus-Host Disease (GvHD)
Sub-specialties
- Acute Leukaemia Management: Induction, consolidation, and maintenance chemotherapy protocols for adult ALL and AML, including FLT3 inhibitors, venetoclax-based regimens, and minimal residual disease-guided therapy.
- Haploidentical Stem Cell Transplantation: Adult haplo-BMT with post-transplant cyclophosphamide for acute leukaemia and sickle cell disease — part of an international learning collaborative on haplo-BMT for SCD.
- Sickle Cell Curative Therapy: Haploidentical stem cell transplantation for adult sickle cell disease, including in medically complex cases with prior solid organ transplantation.
Advanced Procedures & Treatments
- Matched-Related & Haploidentical HSCT
- Post-Transplant Cyclophosphamide (PTCy) Protocols
- Reduced-Intensity Conditioning (RIC)
- Venetoclax-based AML Regimens
- FLT3 Inhibitor Therapy (Midostaurin, Gilteritinib)
- Minimal Residual Disease Monitoring (Flow, Molecular)
- GvHD Prevention and Treatment
- Consolidative Stem Cell Transplantation
Professional Experience
Current Affiliation
- Consultant, Acute Leukaemia — Adult Haematology & Stem Cell Therapy Program, King Faisal Specialist Hospital & Research Centre (KFSHRC), Riyadh, Saudi Arabia (Present)
Past Affiliations
- Fellowship training in Adult Haematology and Stem Cell Transplantation — completed prior to consultancy at KFSHRC
Academic & Research Roles
- Participating investigator — International Learning Collaborative on Haploidentical BMT for Sickle Cell Disease
- Clinical faculty — Adult Haematology and Stem Cell Therapy programmes at KFSHRC
Key Achievements
- Lead author, first published haploidentical stem cell transplant for sickle cell disease after liver transplantation
- Co-investigator in an international learning collaborative on haplo-BMT for SCD
- Active in adult acute leukaemia clinical protocols and transplantation research
- Experienced in treating international patients referred for curative stem cell transplantation
Awards & Recognitions
National & International Awards
- Information not publicly available.
Professional Memberships
- American Society of Hematology (ASH)
- European Society for Blood and Marrow Transplantation (EBMT)
- Saudi Society of Haematology
Research & Publications
Published Papers (Selected)
- Alahmari AD, et al. Haploidentical Stem Cell Transplantation After Liver Transplantation for Sickle Cell Disease. Communications Medicine. 2025. PMC12356966.
- Kassim AA, Alahmari AD, et al. International Learning Collaborative on Haploidentical BMT for Sickle Cell Disease. Blood. 2024;143:2654-2665.
- Alahmari AD, et al. Adult Haematology and Transplantation — Clinical Outcomes Analyses.
Ongoing Research & Clinical Interests
- Haploidentical BMT for adult sickle cell disease
- Post-transplant cyclophosphamide optimisation
- Acute leukaemia minimal residual disease-guided therapy
- Transplant outcomes in medically complex patients
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (INR) | Estimated Cost (USD) |
|---|---|---|
| Haematology Consultation | ₹1,000 – ₹2,500 | $12 – $30 |
| Bone Marrow Biopsy & Aspirate | ₹8,000 – ₹25,000 | $100 – $300 |
| Chemotherapy (per cycle) | ₹40,000 – ₹2,00,000 | $480 – $2,400 |
| Autologous Stem Cell Transplant | ₹12,00,000 – ₹18,00,000 | $14,500 – $21,700 |
| Allogeneic Stem Cell Transplant | ₹18,00,000 – ₹30,00,000 | $21,700 – $36,100 |
| CAR-T Cell Therapy | ₹1,50,00,000 – ₹4,00,00,000 | $180,000 – $480,000 |
*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.
Frequently Asked Questions
1. What advanced technologies does Dr. Ali D. Alahmari use in Adult Haematology — Acute Leukaemia & Stem Cell Therapy treatment?
Dr. Ali D. Alahmari uses advanced acute leukaemia and transplant technologies including haploidentical stem cell transplantation with post-transplant cyclophosphamide, venetoclax-based AML regimens, FLT3 inhibitors (midostaurin, gilteritinib), minimal residual disease (MRD) monitoring, reduced-intensity conditioning for complex patients, and GvHD prophylaxis protocols. Virtual consultations and remote second opinions are also available to international patients through Cancer Rounds.
2. What conditions does Dr. Ali D. Alahmari specialize in treating?
Dr. Ali D. Alahmari specialises in Acute Leukaemia and Adult Stem Cell Therapy, treating acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML), myelodysplastic syndrome (MDS), adult sickle cell disease, beta-thalassaemia, aplastic anaemia, and graft-versus-host disease (GvHD). International patients seeking the best acute leukaemia doctor in India or Saudi Arabia benefit from his haplo-BMT expertise.
3. How do I book an appointment with Dr. Ali D. Alahmari?
Appointments with Dr. Ali D. Alahmari can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Dr. Ali D. Alahmari?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Dr. Ali D. Alahmari, including medical visa invitation letters, airport transfers, and local accommodation coordination.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation, financial counselling, and pre-travel virtual consultations to review medical records before arrival.
6. Does Dr. Ali D. Alahmari offer second opinions for Adult Haematology — Acute Leukaemia & Stem Cell Therapy cases?
Yes. Second opinion consultations for Acute Leukaemia and stem cell transplantation cases can be arranged via Cancer Rounds, enabling international patients to review transplant eligibility, MRD status, and conditioning regimen selection with Dr. Ali D. Alahmari.
